Author/Authors :
Demir, Cengiz Yuzuncu Yil University - Faculty of Medicine - Department of Hematology, Turkey , Turan, Nedim Yuzuncu Yil University - Faculty of Medicine - Department of Medical Oncology, Turkey , Şehitoğulları, Abidin Van Training and Research Hospital - Clinic of Thoracic Surgery, Turkey , Esen, Ramazan Yuzuncu Yil University - Faculty of Medicine - Department of Hematology, Turkey
Abstract :
Dasatinib is a tyrosine kinase inhibitor which is used for the treatment of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib. Dasatinib can cause fluid retention in some patients, leading to peripheral edema and pleural effusion. Recognition of these symptoms as a potential complication of dasatinib will help prevent unnecessary investigations and facilitate adequate management. We report a patient with blastic phase CML. In patients with advanced phase CML an initial dose of dasatinib is recommended as 70 mg twice daily. We observed that 100 mg once daily dose of dasatinib could control the blastic phase of CML with less toxicity.
Keywords :
Chronic , dasatinib , malignant , myeloid leukemia , pleural effusion
